



**Amendments to and Listing of the Claims:**

Please amend claims 1 and 3 - 5, without prejudice, and cancel claims 8-10, without prejudice, as indicated in the following listing of the claims:

1. (Currently Amended) A compound of general formula (I)



wherein R is a group of general formula (A):



wherein

R<sub>1</sub> and R<sub>3</sub> are independently selected from the substituted and unsubstituted group consisting of C<sub>1</sub>-C<sub>10</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkenyl, C<sub>2</sub>-C<sub>10</sub>-alkenyl, C<sub>6</sub>-C<sub>14</sub>-aryl and a heterocycle, and hydrogen;

R<sub>2</sub> is selected from the substituted and unsubstituted group consisting of C<sub>1</sub>-C<sub>6</sub>-alkylene, C<sub>3</sub>-C<sub>6</sub>-cycloalkylene, C<sub>3</sub>-C<sub>6</sub>-cycloalkenylene, C<sub>2</sub>-C<sub>6</sub>-alkenylene, C<sub>6</sub>-C<sub>14</sub>-arylene and a heterocycle;


R<sub>1</sub> and R<sub>2</sub> and/or R<sub>2</sub> and R<sub>3</sub> can form an heterocycle optionally containing further nitrogen atoms;

Y is a physiologically compatible anion;


i and n are independently natural numbers  $\geq 1$ , and

physiologically compatible addition salts,


provided that R is not:



and that if Y is  $\text{NO}_3^-$ , R is not




and that if Y is  $\text{NO}_3^-$ ,  $[\text{ClO}_4^-]$  or  $[\text{Cl}^-]$ , R is not




2. (Original) The compound according to claim 1, wherein Y in general formula (I) is SCN.

3. (Currently Amended) A method of treating a cancer disease comprising administering to a subject having a cancer disease a medicament, containing a pharmaceutical carrier and a compound of general formula (I)



wherein R is a group of the general formula (A)



wherein

R<sub>1</sub> and R<sub>3</sub> are independently selected from the substituted and unsubstituted group consisting of C<sub>1</sub>-C<sub>10</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkenyl, C<sub>2</sub>-C<sub>10</sub>-alkenyl, C<sub>6</sub>-C<sub>14</sub>-aryl and a heterocycle, and hydrogen;

R<sub>2</sub> is selected from the substituted and unsubstituted group consisting of C<sub>1</sub>-C<sub>6</sub>-alkylene, C<sub>3</sub>-C<sub>6</sub>-cycloalkylene, C<sub>3</sub>-C<sub>6</sub>-cycloalkenylene, C<sub>2</sub>-C<sub>6</sub>-alkenylene, C<sub>6</sub>-C<sub>14</sub>-arylene and a heterocycle;

R<sub>1</sub> and R<sub>2</sub> and/or R<sub>2</sub> and R<sub>3</sub> can form an heterocycle optionally containing further nitrogen atoms;


Y is a physiologically compatible anion;

i and n are independently natural numbers  $\geq 1$ , and


physiologically compatible addition salts;

the compound of general formula (I) being present in an amount effective to treat a cancer disease.

4. (Currently Amended) The medicament-method according to claim 3, wherein R in general formula (I) is:



5. (Currently Amended) The medicament-method according to claim 3, wherein R in general formula (I) is:



6. (Previously Presented) A method of treating a cancer disease comprising administering to a subject having a cancer disease a compound of general formula (I) according to claim 1.

7. (Previously Presented) A method of treating a cancer disease comprising administering to a subject having a cancer disease a compound of general formula (I) according to claim 2.

8. to 10. (Canceled)